The proposal is to implement a molecular screening program for advanced/metastatic pancreatic cancer patients before the initiation of 1st line treatment in order to allow a better selection of patients for rationale personalized medicine with targeted agents and/or combination involving a chemotherapy backbone.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
SCREENING
Masking
NONE
Enrollment
750
Molecular screening
Centre Léon Bérard
Lyon, France
RECRUITINGNumber of patients with at least one actionable alteration defined as an alteration shown to predict for sensitivity to a drug FDA/EMA approved for use in another cancer type, or a relevant alteration for inclusion in a clinical trial.
Time frame: At the end of study (5 years)
Time from ICF signature to day 1 of next line of therapy
Time frame: At day 1
Number of patients initiating a targeted therapy according to this molecular screening program with type of therapy initiated
Time frame: At the end of study (5 years)
Progression-Free Survival (PFS)
Time frame: Up to 12 months
Best overall response (BoR)
Time frame: Up to 12 months
Overall survival (OS)
Time frame: Up to 12 months
Duration of response (DoR)
Time frame: Up to 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.